OptiBiotix Health PLC CholBiome® agreement for Greece and Cyprus (1203I)
November 22 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 1203I
OptiBiotix Health PLC
22 November 2018
OptiBiotix Health plc
("OptiBiotix")
CholBiome(R) agreement for Greece and Cyprus
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol and diabetes, announces it has entered into a three
year distribution agreement with an established and recognised
company ("The Company") to exclusively distribute and commercialise
OptiBiotix's own label CholBiome(R) products containing its
cholesterol and blood pressure reducing LP(LDL) (R) strain, in
Greece and Cyprus.
The Company is a rapidly growing firm with an established
distribution network in Cyprus, Greece and the Middle East with a
track record in new product promotion and market development in
pharmaceutical and foods supplement distribution directly to
pharmacies. The Company is associated with a number of
international clinics, providing biological medicine therapies to
individuals across the world.
The agreement grants the Company exclusive distribution in
return for local product registration and three year's sales
targets to retain exclusivity. This agreement covers the
CholBiome(R) range and follows our recent launch online in the UK
and the announcement on 26 September 2018 of a CholBiome(R)
distribution agreement for Bulgaria. It is in line with our
strategy to expand sales of OptiBiotix's own label CholBiome(R)
products into the European market.
CholBiome(R) products containing LP(LDL) (R) have a unique
ability to reduce both cholesterol and blood pressure providing a
clinically proven natural product to help reduce these
cardiovascular risk factors.
The Company requires its identity and the terms of the agreement
to remain confidential to protect its commercial interests and
launch plans therefore no further details can be disclosed. A
further announcement will be made in due course.
Per Rehné, Commercial Director of OptiBiotix, commented: "We are
pleased to announce this agreement which extends the sales of our
CholBiome(R) products into Cyprus and Greece. We chose the Company
for its market access in Cyprus and Greece and solid track record
for growing product sales. This agreement is a strategic step to
build the distribution sales channel for CholBiome(R) products in
the European market and eliminates intermediates in the supply
chain with shorter route to market and higher value to OptiBiotix.
The Company has already placed an initial order to be used for
pre-marketing activities and we expect further orders to support a
consumer launch in Q1 2019."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRBBBATMBITBMP
(END) Dow Jones Newswires
November 22, 2018 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024